


王琳（副）教授



一、基本情况

王琳，山东威海，博士，副教授，rushanwanglin@126.com。

二、学习及工作经历

2008年09月--2012年06月	中国药科大学药学院，本科
2012年09月--2017年06月	中国药科大学药学院，博士
2017年07月--2019年12月	烟台药物研究所，工程师
2020年01月--至今	烟台大学，教师

三、目前研究领域

- (1) 药物代谢动力学
- (2) 中药药效物质基础研究

四、社会兼职

无

五、主要科研成果

1. 靶向 DPP-4 的新型降糖药物 LC-26 的药代-药效协同研究，烟台市科技发展计划，主持
2. 基于阻断 AHA1-HSP90 相互作用的 AHA1 小分子抑制剂的发现及其抗复发难治性多发性骨髓瘤研究，山东省自

然科学基金，参与

六、教学工作

1. 研究生：临床药代动力学
2. 本科生：分析化学、简明分析化学、药物分析实验、仪器分析实验

七、目前承担科研项目情况

1. 褐藻多糖硫酸酯的体内时空命运研究。国家药品监督管理局糖药物质量研究与评价重点实验室开放课题，项目编号：2024QRECM04，2024.11-2026.11，课题主持人。

八、发表论文

1. Qian F, Ouyang B1, Cai Z, Zhu D, Yu S, Zhao J, Wei N, Wang G, **Wang L***, Zhang J*. Compound Shouwu Jiangzhi Granule regulates triacylglyceride synthesis to alleviate hepatic lipid accumulation. *Phytomedicine*. 2024 Jul;129:155691.
2. Li Z, Du Y, Ding C, Yang P, **Wang L***, Zhao Y*. An Interpretable Screening Approach Derived Through XGBoost Regression for the Discovery of Hypolipidemic Contributors in Chinese Hawthorn Leaf and its Counterfeit Malus Doumeri Leaf. *Plant Foods Hum Nutr*. 2024 Mar;79(1):209-218.
3. Su M, Liu X, Zhao Y, Zhu Y, Wu M, Liu K, Yang G, Liu W*, **Wang L***. In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease. *Molecules*. 2023 Dec 27;29(1):159.

4. **Wang L**, Lei H, Lu J, Wang W, Liu C, Wang Y, Yang Y, Tian J*, Zhang J*. Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS. *Molecules*. 2023 Mar 10;28(6):2550.
5. Lin C, Kong Y, Wang F, Rong R, Li X, Xiao R, Wu Z, Zhang Q*, **Wang L***. Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. *Bioorg Chem*. 2022 Jun;123:105767.
6. **Wang L**, Li X, Kong Y, Wang F, Zhang Q, Lin C*, Rong R*. Pharmacokinetics, tissue distribution and excretion of compound 6c, a novel DPP-4 inhibitor, following intragastric administration in rats by ultra-performance liquid chromatography-tandem mass spectrometry. *Eur J Pharm Sci*. 2022 Jun 1;173:106162.
7. **Wang L**, Wang J, Lin C, Wang F, Li X, Liu W*. Simultaneous Quantification of Pioglitazone and Omarigliptin in Rat Plasma by UHPLC-MS/MS and Its Application to Pharmacokinetic Study after Coadministration of the Two Drugs. *J Anal Methods Chem*. 2021 Jun 7;2021:6693366.
8. **Wang L**, Li X, Kong Y, Zhang Q, Xie H*. Development of a sensitive UHPLC-MS/MS method for the pharmacokinetics study of a novel tyrosine kinase inhibitors, 1-[4-(4-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-

ylamino}-phenyl)-piperazin-1-yl]-propanone in rats. *Biomed Chromatogr.*

2021 May;35(5): e5059.

9. Lin C*, Li P, **Wang L***. Visible-light induced Cross-Dehydrogenative-Coupling (CDC) reactions of N-aryl tetrahydroisoquinolines under aerobic conditions. *Tetrahedron Letters*, 2021, 73: 153102.

10. Sun S, Cheng D, Kong S, Li X, Li T, Yu Q, **Wang L***. A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline. *Biomed Chromatogr.* 2020 Jan;34(1):e4703.